|
79
|
239
|
4u7oA |
Active histidine kinase bound with atp |
|
69
|
225
|
4u7nA |
Inactive structure of histidine kinase |
|
73
|
208
|
4qpkA |
1.7 angstrom structure of a bacterial phosphotransferase |
|
66
|
209
|
4r3mA |
Crystal structure of human hsp90 with jr9 |
|
113
|
394
|
4r1fA |
Re-refined human dna topoisomerase iia (atpase and transducer domains) in complex with adp and so4 |
|
67
|
208
|
4qpjA |
2.7 angstrom structure of a phosphotransferase in complex with a receiver domain |
|
99
|
331
|
4r3aA |
Erythrobacter litoralis el346 blue-light activated histidine kinase |
|
108
|
374
|
4prxA |
E. coli gyrb 43-kda n-terminal fragment in complex with adp+pi |
|
123
|
385
|
4pu9A |
E. coli gyrb 43-kda n-terminal fragment in complex with adp-bef3 |
|
124
|
382
|
4prvA |
E. coli gyrb 43-kda n-terminal fragment in complex with adp |
|
57
|
184
|
4p8oA |
S. aureus gyrase bound to an aminobenzimidazole urea inhibitor |
|
88
|
334
|
4p7aA |
Crystal structure of human mlh1 |
|
42
|
176
|
4pl9A |
Structure of the catalytic domain of etr1 from arabidopsis thaliana |
|
77
|
233
|
4q20A |
Crystal structure of a c-terminal part of tyrosine kinase (divl) from caulobacter crescentus cb15 at 2.50 a resolution (psi community target, shapiro) |
|
66
|
209
|
4o05A |
Identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease |
|
55
|
265
|
4nh9A |
Correlation between chemotype-dependent binding conformations of hsp90 alpha/beta and isoform selectivity |
|
67
|
209
|
4o07A |
Identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease |
|
68
|
209
|
4nh8A |
Correlation between chemotype-dependent binding conformations of hsp90 alpha/beta and isoform selectivity |
|
70
|
208
|
4nh7A |
Correlation between chemotype-dependent binding conformations of hsp90 alpha/beta and isoform selectivity |
|
67
|
209
|
4o0bA |
Identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease |
|
69
|
209
|
4o09A |
Identification of novel hsp90 / isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington s disease |
|
66
|
208
|
4o04A |
Identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease |
|
68
|
207
|
4lwfA |
Crystal structure of the human hsp90-alpha n-domain bound to the hsp90 inhibitor fj3 |
|
60
|
210
|
4motA |
Structure of streptococcus pneumonia pare in complex with az13072886 |
|
68
|
208
|
4lwhA |
Crystal structure of the human hsp90-alpha n-domain bound to the hsp90 inhibitor fj5 |
|
58
|
210
|
4lp0A |
Crystal structure of a topoisomerase atp inhibitor |
|
137
|
383
|
4mp7A |
Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor pa7 |
|
61
|
210
|
4mb9A |
Structure of streptococcus pneumonia pare in complex with az13102335 |
|
62
|
207
|
4lwiA |
Crystal structure of the human hsp90-alpha n-domain bound to the hsp90 inhibitor fj6 |
|
132
|
383
|
4mpcA |
Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor ps2 |
|
68
|
207
|
4lwgA |
Crystal structure of the human hsp90-alpha n-domain bound to the hsp90 inhibitor fj4 |
|
60
|
210
|
4lpbA |
Crystal structure of a topoisomerase atpase inhibitor |
|
135
|
383
|
4mpnA |
Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor ps10 |
|
62
|
210
|
4mbcA |
Structure of streptococcus pneumonia pare in complex with az13053807 |
|
68
|
208
|
4lweA |
Crystal structure of the human hsp90-alpha n-domain bound to the hsp90 inhibitor fj2 |
|
135
|
383
|
4mpeA |
Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor ps8 |
|
137
|
381
|
4mp2A |
Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor pa1 |
|
71
|
208
|
4l8zA |
Crystal structure of human hsp90 with rl1 |
|
69
|
208
|
4l90A |
Crystal structure of human hsp90 with rl3 |
|
62
|
210
|
4k4oA |
The dna gyrase b atp binding domain of enterococcus faecalis in complex with a small molecule inhibitor |
|
68
|
207
|
4l94A |
Crystal structure of human hsp90 with s46 |
|
108
|
374
|
4kqvA |
Topoisomerase iv atp binding domain of francisella tularensis in complex with a small molecule inhibitor |
|
60
|
210
|
4ktnA |
Dna gyrase atp binding domain of enterococcus faecalis in complex with a small molecule inhibitor ((3s)-1-[2-(pyrido[2,3-b]pyrazin-7-ylsulfanyl)-9h-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-amine) |
|
59
|
205
|
4kfgA |
The dna gyrase b atp binding domain of escherichia coli in complex with a small molecule inhibitor. |
|
62
|
210
|
4ksgA |
Dna gyrase atp binding domain of enterococcus faecalis in complex with a small molecule inhibitor (4-[(1s,5r,6r)-6-amino-1-methyl-3-azabicyclo[3.2.0]hept-3-yl]-6-fluoro-n-methyl-2-[(2-methylpyrimidin-5-yl)oxy]-9h-pyrimido[4,5-b]indol-8-amine) |
|
70
|
207
|
4l91A |
Crystal structure of human hsp90 with x29 |
|
59
|
210
|
4kshA |
Dna gyrase atp binding domain of enterococcus faecalis in complex with a small molecule inhibitor (7-({4-[(3r)-3-aminopyrrolidin-1-yl]-5-chloro-6-ethyl-7h-pyrrolo[2,3-d]pyrimidin-2-yl}sulfanyl)-1,5-naphthyridin-1(4h)-ol) |
|
67
|
207
|
4l93A |
Crystal structure of human hsp90 with s36 |
|
66
|
219
|
4kp4A |
Deciphering cis-trans directionality and visualizing autophosphorylation in histidine kinases. |
|
76
|
241
|
4jauA |
Structural basis of a rationally rewired protein-protein interface (hk853mutant a268v, a271g, t275m, v294t and d297e) |
